The Pharmaceutical Industry: Development and Marketing of Prescription Drugs

1986 ◽  
pp. 500-509
Author(s):  
Jerald A. Breitman
Keyword(s):  
Pharmaceutical Industry ◽  
Prescription Drugs ◽  
Industry Development

Introduction

2021 ◽  
pp. 3-13
Author(s):  
Neumann Peter J. ◽  
Cohen Joshua T. ◽  
Ollendorf Daniel A
Keyword(s):  
Pharmaceutical Industry ◽  
Prescription Drug ◽  
Prescription Drugs ◽  
Health Expenditures ◽  
Drug Spending ◽  
Drug Pricing ◽  
Pricing Policies ◽  
Drug Prices ◽  
Financial Difficulties ◽  
Prescription Drug Spending

The pharmaceutical industry has produced wondrous scientific advances, but the progress has come at a cost. US prescription drug spending has increased faster in most recent years than other categories of health and now comprises roughly one-sixth of total health expenditures. Rising costs strain already stretched public budgets. Increasing patient out-of-pocket spending for deductibles and coinsurance has created financial difficulties for many individuals and their families, particularly among the sickest patients. The dueling trends of scientific breakthroughs and ever-rising spending present enduring challenges. On its own, rising spending would not be so concerning, but evidence suggests that drug prices often do not reflect the benefits they provide. Thus, there is an imperative to measure the value of prescription drugs and incorporate such measures into drug pricing policies.

scholarly journals “Daltexpharma”: A Case Addressing Potential Pharmaceutical Cargo Theft

2020 ◽  
Vol 11 (3) ◽  
pp. 16
Author(s):  
Tiffany M. Marchione ◽  
Nile M. Khanfar ◽  
Bahaudin G. Mujtaba ◽  
David Loudon
Keyword(s):  
Pharmaceutical Industry ◽  
Prescription Drugs ◽  
The United States ◽  
Security Measures ◽  
Article Type ◽  
Last Mile ◽  
Security Practices ◽  
Method Of Instruction ◽  
Cargo Theft ◽  
Faculty Instruction

Case Synopsis This paper is provided as an innovative resource for those in the academic and training arenas to use as a case example in discussing the problem of pharmaceutical cargo theft.  The case delves into the worldwide, on-going dilemma of pharmaceutical trucking cargo theft losses and the effects of such theft.  For those unfamiliar with the case method of instruction, the paper’s ending may be rather unsettling.  But that is where the student’s learning and faculty instruction process come together.  Typically, students (whether in teams or individually) will fully develop their responses based on the queries provided at the end.  Faculty may then proceed in any number of ways to elicit the students’ insights in a classroom setting.  For decades the pharmaceutical industry has been plagued with a plethora of criminal acts that impact the daily processes and procedures of operations.  Pharmaceutical warehouse and trucking thefts have not only aided in the currently debilitating state of the opioid crisis in the United States, but these thefts also aid the black market in the illegal sale of diverted prescription drugs.  Due to the lack of security measures, vulnerability of the truck drivers, their rigs, and the value of the cargo being transported, pharmaceutical theft is a lucrative opportunity for organized crime.  The case presented here describes the issues within the pharmaceutical industry as companies must deal with “last mile” cargo thefts.  Daltexpharma represents a synthesized, hypothetical example of a pharmaceutical firm that must develop policies to deal with such potential thefts in its supply chain.  Although a fictitious company, the case realistically details the important factors to consider in establishing strong security practices that may be necessary for a pharmaceutical company operating in today’s environment.  In order to protect the integrity and security of the authors’ case notes, particularly for use in an academic setting, the Journal’s editor will maintain control of them.  They may be obtained by faculty upon presenting their request to the Editor.    Article Type: Instructional Tool

Blockbuster Drugs

2014 ◽  
Author(s):  
Jie Jack Li
Keyword(s):  
Drug Discovery ◽  
Pharmaceutical Industry ◽  
Prescription Drugs ◽  
Business Models ◽  
Scientific Discovery ◽  
New Drugs ◽  
Pharmaceutical Companies ◽  
Blockbuster Drug ◽  
A Minor ◽  
Future Landscape

For the world's largest prescription drug manufacturers, the last few years have been a harrowing time. Recently, Pfizer's Lipitor, GlaxoSmithKline's Advair, AstraZeneca's Seroquel, and Sanofi-Aventis and Bristol-Myers Squibb's Plavix all came off patent in the crucial U.S. market. This so-called "patent cliff" meant hundreds of billions of dollars in lost revenue and has pharmaceutical developers scrambling to create new drugs and litigating to extend current patent protections. Having spent most of his career in drug discovery in "big pharma," Dr. Li now delivers an insider's account of how the drug industry ascended to its plateau and explores the nature of the turmoil it faces in the coming years. He begins with a survey of the landscape before "blockbuster drugs," and proceeds to describe how those drugs were discovered and subsequently became integral to the business models of large pharmaceutical companies. For example, in early 1980s, Tagamet, the first "blockbuster drug," transformed a minor Philadelphia-based drug maker named SmithKline & French into the world's ninth-largest pharmaceutical company in terms of sales. The project that delivered Tagamet was nearly terminated several times because research efforts begun in 1964 produced no apparent results within the first eleven years. Similar stories accompany the discovery and development of now-ubiquitous prescription drugs, among them Claritin, Prilosec, Nexium, Plavix, and Ambien. These stories, and the facets of the pharmaceutical industry that they reveal, can teach us valuable lessons and reveal many crucial aspects about the future landscape of drug discovery. As always, Dr. Li writes in a readable style and intersperses fascinating stories of scientific discovery with engaging human drama.

An Analysis of the Medical Supply Industries

1976 ◽  
Vol 6 (2) ◽  
pp. 271-294 ◽  
Author(s):  
Meredeth Turshen
Keyword(s):  
United Kingdom ◽  
Pharmaceutical Industry ◽  
Multinational Corporations ◽  
Prescription Drugs ◽  
Medical Science ◽  
Food Additives ◽  
Patent System ◽  
Medical Supply ◽  
Underdeveloped Countries ◽  
The United Kingdom

Medical supply industries are dominated by widely diversified multinational companies that produce chemicals, pharmaceuticals, computers, cosmetics, and electronic equipment. Of these products, the most profitable group is prescription drugs. This article contains a description of the general structure of the pharmaceutical industry worldwide and the specific details of drug operations in the United Kingdom. The United Kingdom is of special interest because of its long-standing and partially successful attempt to regulate drug prices. The government's inability to achieve total control is related to the competitive structure of capitalist economy, to the patent system that grants monopoly privileges to drug firms, and to the duplication of research efforts and waste of resources that push up drug costs. The pharmaceutical industry serves the needs of people poorly in developed countries; its impact on underdeveloped countries is much worse. In the Third World, nascent national companies and small local producers of drugs cannot compete with the huge multinationals; the patent system proves to be an imperfect mechanism for the transfer of medical science and technology; and the high cost of imported drugs determines the amount of health care governments can provide for the population. The multinational corporations are now global enterprises that integrate the production of chemicals for many different uses-drugs for human and animal consumption, fertilizers, pesticides, and food additives. Thus the multinationals affect agricultural production and animal husbandry in underdeveloped countries and thereby nutrition as well as the treatment of disease.

The Future of the Pharmaceutical Industry: Beyond Government-Granted Monopolies

2021 ◽  
Vol 49 (1) ◽  
pp. 25-29
Author(s):  
Dean Baker
Keyword(s):  
Pharmaceutical Industry ◽  
Prescription Drugs ◽  
The Future ◽  
Order Of Magnitude ◽  
The Impact

AbstractJust as tariffs lead to economic distortions and provide incentives for corruption, so do patent monopolies on prescription drugs, except the impact is often an order of magnitude larger.

Sign in / Sign up

Export Citation Format

Share Document